Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Carcinoma, Hepatocellular: early-phase trial registry
7 of 28 indexed Carcinoma, Hepatocellular trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #577 of 28,707 conditions by registered trial count.
28 US clinical trials · 7 currently recruiting · #577 of 28,707 conditions by registered trial count
Carcinoma, Hepatocellular: 28 US clinical trials tracked, 7 recruiting.
Carcinoma, Hepatocellular is the subject of 28 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 7 are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most active sponsor is Bayer, running 5 of these trials.
Enrollment posture brief
Registry condition carcinoma-hepatocellular
OPEN 7 | RECR 25% | LATE 7 | EARLY 14 | RANK #577 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
Carcinoma, Hepatocellular lists 7 open slots (25% of 28 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Carcinoma, Hepatocellular on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Carcinoma, Hepatocellular is recruiting below its size-band peers.
7 of 28 indexed trials (25%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Carcinoma, Hepatocellular research.
Bayer accounts for 5 of 28 trials (17.9%). 19 distinct sponsors appear on at least one study for this condition label.
-
Typical Carcinoma, Hepatocellular enrolment sits around 84 participants.
Median target enrolment is 84 among the 28 trials that report a genuine target (sentinel values excluded). 16 of those (57.1%) plan for fewer than 100 participants.
-
Carcinoma, Hepatocellular research is mostly interventional.
24 interventional and 4 observational studies make up this index (85.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
28 total, page 1 of 1
National Liver Cancer Screening Trial
University of Texas Southwestern Medical Center
NCT06084234
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
VA Office of Research and Development
NCT05486572
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
Travera
NCT05461430
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
The University of Texas Health Science Center at San Antonio
NCT03894917
90Y Transarterial Radioembolization Versus Microwave Ablation in Small Hepatocellular Carcinoma With Hypoalbuminemia
Ochsner Health System
NCT05953961
ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
Abivax S.A.
NCT03897543
Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma
Rutgers, The State University of New Jersey
NCT05366829
Case-Control Study of the Glycotest™ HCC Panel Vs AFP for the Detection of Early-stage Hepatocellular Carcinoma
Glycotest
NCT03878550
A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
Hoffmann-La Roche
NCT04102098
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
Merck Sharp & Dohme
NCT04246177
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
Eisai
NCT04008797
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Carisma Therapeutics
NCT04660929
Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)
Bayer
NCT00692770
Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma
Bayer
NCT00901901
A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Bayer
NCT00105443
A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
Hoffmann-La Roche
NCT03434379
A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Hoffmann-La Roche
NCT01507168
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
Eisai
NCT05091346
A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer
Bristol-Myers Squibb
NCT05337137
Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors
Southwestern Regional Medical Center
NCT00493883
Safety and Effectiveness of BioTraceIO Lite for Tissue Damage Assessment Following Liver Tissue Ablation Procedures
Techsomed Medical Technologies
NCT04970212
A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases
Hoffmann-La Roche
NCT04338685
Sorafenib and TRC105 in Hepatocellular Cancer
National Cancer Institute (NCI)
NCT01306058
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
Bayer
NCT01915589
Advanced Image Guidance Utilized in Liver Surgery
Wake Forest University Health Sciences
NCT01666145
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
Bayer
NCT01915602
Meclizine for Hepatocellular Carcinoma
Tannaz Armaghnay
NCT03253289
TRC105 for Liver Cancer That Has Not Responded to Sorafenib
National Cancer Institute (NCI)
NCT01375569
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 5 |
| Phase 3 | 6 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Carcinoma, Hepatocellular records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Carcinoma, Hepatocellular trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Carcinoma, Hepatocellular page
28 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Carcinoma, Hepatocellular trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Bayer sponsors the most Carcinoma, Hepatocellular trials on record, review their full trial history before evaluating a specific study. See Bayer's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Carcinoma, Hepatocellular condition card totals 28 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.